ESR1 and breast lobular carcinoma: Alongside our experience in IORT delivered as a boost [4,5], we decided many years ago to extend this concept to a specific very low-risk population (i.e. age ≥ 65 years old, tumor size < 2 cm, non-lobular carcinoma and estrogen receptor positivity) for a unique and exclusive treatment.